PSA Response Improvement: Promising Data from Pluvicto in mHSPC Treatment
New data from the PSMAddition study indicate that Pluvicto combined with standard of care, consisting of an androgen receptor pathway inhibitor plus androgen deprivation therapy, produced a 58% lower risk of prostate-specific antigen progression compared with standard of care alone. Patients receiving the combination also demonstrated higher rates of deep PSA reductions, with nearly all participants in both arms showing substantial declines yet a greater proportion achieving a PSA nadir below 0.2 ng/mL when Pluvicto was added. These findings were presented at the American Urological Association Annual Meeting 2026 and form the basis for supplemental new drug applications filed in the United States, China, and Japan, with regulatory decisions anticipated in the second half of 2026.
Deeper PSA Declines with Added Pluvicto
The combination regimen yielded more frequent and profound PSA responses across multiple time points, as evidenced by 47.6% of patients reaching PSA levels below 0.2 ng/mL at week 12 versus 37.7% with standard of care alone, rising to 73.7% versus 59.7% at week 24 and 87.4% versus 74.9% at week 48. Such patterns underscore a more durable suppression of prostate-specific antigen, an early marker of emerging treatment resistance that affects approximately one-third of patients managed with standard of care. Safety data remained consistent with prior trials, with grade 3 or higher adverse events occurring in 50.7% of the combination arm compared with 43% in the control arm, primarily involving manageable effects such as dry mouth, fatigue, and anemia.
PSMAddition Trial Design and Targeted Approach
The reported outcomes derive from the second interim analysis of PSMAddition, a phase 3 evaluation of lutetium (177Lu) vipivotide tetraxetan in PSMA-positive metastatic hormone-sensitive prostate cancer. The trial assessed radiographic progression-free survival alongside PSA endpoints, confirming that the radioligand therapy binds selectively to prostate-specific membrane antigen-expressing cells, delivering targeted radiation that disrupts replication and induces cell death. This approach builds on earlier demonstrations of clinical benefit in metastatic castration-resistant prostate cancer, extending the evaluation to an earlier disease setting where progression to castration resistance typically occurs within 20 months and is linked to markedly reduced survival.
Shifting Paradigms in Prostate Cancer Care
These PSA Response Improvement findings suggest opportunities for earlier treatment intensification that could delay progression to metastatic castration-resistant prostate cancer, a state associated with life expectancy under two years and substantial resource utilization. For health economics and outcomes research, the data support modeling of extended progression-free intervals that may influence market access strategies, pricing negotiations, and reimbursement decisions by demonstrating added clinical value over androgen receptor pathway inhibitor plus androgen deprivation therapy alone. Broader industry movement toward precision-based radioligand therapies could further shape payer evaluations, particularly as regulatory submissions advance and real-world evidence on tolerability and healthcare utilization accumulates.
